Collectively, these results indicate that Beclin 1 down-regulation renders the AML cells sensitive to necroptotic cell death, implying that Beclin 1 can be used as a plausible therapeutic target for necroptosis-induced anti-tumour therapy. Here, BECN1 is linked to acute myeloid leukemia.